NuGen Medical Devices Inc. (NGMDF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 0 | 0 | 0 | 0 | 1 | 0 | 0 | - |
| Operating profit | CAD m | -4 | -5 | ||||||
| Net profit | CAD m | -4 | -7 | -6 | -9 | -5 | -8 | -10 | - |
| EPS reported | CAD | -0.03 | -0.04 | ||||||
| Operating cashflow per share | CAD | -0.02 | -0.02 | ||||||
| Capex per share | CAD | 0.00 | 0.00 | ||||||
| FCF per share | CAD | -0.02 | -0.02 | ||||||
| Free cash flow | CAD m | -4 | -5 | ||||||
| Net debt | CAD m | 14 | 18 | ||||||
| Book value equity | CAD m | -14 | -17 | ||||||
| Book value per share | CAD | -0.06 | -0.08 | ||||||
| Number of shares | m | 226.9 | 227.04 | ||||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.57 | -0.45 | ||||||
| P/S LTM | x | 30.20 | 52.39 | ||||||
| P/FCF LTM | x | -2.01 | -1.62 | ||||||
| EV/EBITDA LTM | x | -6.23 | -5.64 | ||||||
| EV/Sales LTM | x | 85.20 | 127.52 | ||||||
| Earnings Yield LTM | % | -1.00% | -2.20% | ||||||
| FCF Yield | % | -49.68% | -61.59% | ||||||
| Quality | |||||||||
| ROE | % | +56.98% | +99.20% | ||||||
| ROIC | % | -1.16% | -1.80% | ||||||
| Operating margin | % | -16.36% | -27.66% | ||||||
| Gross margin | % | -2.17% | -1.72% | ||||||
| FCF/Sales | % | -1500.1% | -2661.1% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -74.48% | -85.29% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.22 | -0.26 | ||||||
| Net Debt/EBITDA | x | -4.02 | -3.71 | ||||||
| EBIT/Net interest | x | -1.38 | -1.39 | ||||||
| Net debt/market cap | % | +2.23% | +3.58% | ||||||
| Net debt/Equity | x | -1.03 | -1.05 | ||||||
| Gross debt/equity | x | -1.27 | -1.09 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
NuGen Medical Devices Inc. is a specialized firm dedicated to pioneering and marketing advanced drug delivery solutions. The company's core offering comprises innovative needle-free injection devices and systems, designed for subcutaneous medication delivery across a broad spectrum of medical conditions and therapeutic applications. These include treatments for anaphylaxis, diabetes management, severe migraine, erectile dysfunction, chronic anemia, neutropenia, and autoimmune rheumatoid arthritis, further extending to growth and fertility hormone therapies, psoriasis treatment, and various vaccine types including DNA, conventional, and pediatric formulations. Previously, the organization operated under the name BuzBuz Capital Corp., and its operational base is situated in Toronto, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
NuGen Medical Devices Inc. is a specialized firm dedicated to pioneering and marketing advanced drug delivery solutions. The company's core offering comprises innovative needle-free injection devices and systems, designed for subcutaneous medication delivery across a broad spectrum of medical conditions and therapeutic applications. These include treatments for anaphylaxis, diabetes management, severe migraine, erectile dysfunction, chronic anemia, neutropenia, and autoimmune rheumatoid arthritis, further extending to growth and fertility hormone therapies, psoriasis treatment, and various vaccine types including DNA, conventional, and pediatric formulations. Previously, the organization operated under the name BuzBuz Capital Corp., and its operational base is situated in Toronto, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free